Contact Us
Home » Products & Applications » Target Enrichment
  • afb97449-9c0a-4c41-b493-fe7ce18c1276

    LeXso AML Panel v1.0

    Catalog Number:
    • #LX11412
    • #LX11411

    LeXso AML MRD Comprehensive Solution: Ultra-Sensitive Monitoring for Acute Myeloid Leukemia

    The LeXso AML MRD Comprehensive Solution is a high-performance platform based on advanced liquid-phase hybridization target enrichment technology. Specifically engineered for adult Acute Myeloid Leukemia (AML) Minimal Residual Disease (MRD) research, this solution provides the sensitivity and speed required to track low-frequency clones and assess molecular response with clinical-grade precision.

    High-Sensitivity, Same-Day Workflow

    By combining adapter identifiers with the patented LeXso hybrid capture system, this solution eliminates background noise and sequencing artifacts to achieve ultra-high detection sensitivity. The streamlined chemistry is designed for high-velocity laboratories, enabling the entire experimental process—from library to results—to be completed within a single day.

    Targeted Precision: LeXso AML Panel v1.0

    At the core of this solution is the LeXso AML Panel v1.0, a highly curated 42.5 Kb targeted panel covering 32 essential genes associated with adult AML. The panel is designed to detect a comprehensive range of variants, including:

    • Base Substitutions (SNVs)
    • Insertions and Deletions (Indels)
    • Internal Tandem Duplications (e.g., FLT3-ITD)
    • Critical Gene Fusions
    Request Quote
    • Product Details
    • Kit Content
    • FAQ
    • Ordering Information
    • Resources
    Product Features

    Clinically Validated Coverage

    • Selection of MRD targets covers approximately 90% of AML cases, ensuring broad applicability across patient cohorts.
    • According to the AML_OHSU_2022 cohort, ~90% of cases carry at least one mutation, and ~60% carry three or more, providing multiple markers for longitudinal monitoring.

    Precision Engineering

    • Targeted regions were selected through exhaustive references to COSMIC and TCGA databases, as well as current clinical guidelines, to prioritize high-impact mutational hotspots.

    Multi-Modal Detection

    • Simultaneously enrich and analyze SNVs, indels, and fusions within a single 32-gene workflow, maximizing data yield from limited samples.

    LeXPrep Integration

    • Fully compatible with LeXPrep DNA Library Preparation modules, ensuring high library complexity and conversion efficiency for trace MRD samples.
    Workflow

    Gene list
    ASXL1
    Exon 12,13    		BRINP3
    Exon 3,8    		CBL
    Exon 8,9    		CEBPA*
    Full CDS    		DNMT3A
    Exon 8-23    		EZH2
    Exon 4-6,8,13-20    		FLT3
    Exon 14,15,20    		GATA2
    Exon 3-6    		HNRNPK
    Exon 4-6,10,12,15,16    		IDH1
    Exon 4    		IDH2
    Exon 4
    JAK2
    Exon 14    		KIT
    Exon 8,17    		KMT2A†
    Intron 8-10    		KRAS
    Exon 2,3    		MYH11†
    Intron 32    		NPM1
    Exon 10,11    		NRAS
    Exon 2,3    		PHF6*
    Full CDS    		PTEN
    Exon 5,7    		PTPN11
    Exon 3,13    		RAD21*
    Full CDS
    RUNX1*
    Full CDS    		SF3B1
    Exon 14,15    		SMC1A
    EXON 2,9,11,13,15-17,22    		SMC3
    Exon 9,10,13,19,24,25,27    		SRSF2
    Exon 1    		STAG2
    Exon 4,5,7-9,14,16,18,19,24,26-30    		TET2*
    Full CDS    		TP53*
    Full CDS
    U2AF1
    Exon 2    		WT1
    Exon 6-9

    Note：* Indicates that the gene is covered across the entire coding sequence (CDS) region; † Indicates that the gene is covered in fusion-related intronic regions.

    Performance

    CatalogColor Of Tube CapComponentPackage/Storage
    LX11412●LeXso AML Panel v1.0, 16 rxn-20℃
    LX11411●LeXso AML Panel v1.0, 96 rxn-20℃
    Q1. Why is the use of UMI critical for AML MRD research?

    In MRD monitoring, the target mutations often exist at ultra-low frequencies (below 0.1% Allelic Fraction). LeXso incorporates UMI (Unique Molecular Identifiers) during the LeXPrep library construction phase to tag individual DNA molecules. This allows our bioinformatics pipeline to distinguish true biological mutations from PCR errors or sequencing “noise,” which is essential for accurate low-frequency variant calling.

    Q2. Can this panel detect complex structural variations like FLT3-ITDs?

    Yes. The LeXso AML Panel v1.0 and associated bioinformatics pipelines are specifically optimized to resolve challenging structural variants, including internal tandem duplications and gene fusions, which are hallmark prognostic markers in adult AML.

    Q3. Is the solution compatible with automated platforms?

    Absolutely. The LeXso AML MRD workflow is fully validated for use on the LeXBot automation series, providing a “walk-away” solution that minimizes manual intervention and ensures high-throughput reproducibility.

    ProductCatalog
    LeXso AML Panel v1.0, 16 rxnLX11412
    LeXso AML Panel v1.0, 96 rxnLX11411

    For inquiries or to request a formal quotation, please contact us at support@lexigenbio.com

    Product Sheet

    • 1. Brochure

    COA SEARCH

    Find COAs by batch or Catalog number